Movement Disorders clinical trials

Explore recruiting movement disorders clinical trials.

Recruiting movement disorders studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Movement Disorders trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Portugal, Belgium, Spain, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Independent, multicenter, phase IV, randomized, double-blind, parallel-group clinical trial in people with Parkinson's Disease under stable dopaminergic treatment with persistent fatigue symptoms, randomized 1:1 to adjunctive treatment with safinamide (100 mg/day) or rasagiline (1 mg/day) for 24 weeks.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder (BALSAM-3)

Hungary, Romania, Poland, Sweden, Croatia, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HAMLETT; Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A pragmatic single blind RCT of continuation versus discontinuation/ dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A multi-center, open label, longitudinal, observational, 12-week study of Flexilev treatment with the dosing device OraFID and accompanying digital app in Parkinson patients.

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Movement Disorders trials by city

Movement Disorders in Toronto Movement Disorders in Vancouver Movement Disorders in Montreal Movement Disorders in Calgary Movement Disorders in Edmonton Movement Disorders in Ottawa Movement Disorders in Winnipeg Movement Disorders in Quebec City Movement Disorders in Hamilton Movement Disorders in Kitchener Movement Disorders in London Movement Disorders in Halifax Movement Disorders in New York Movement Disorders in Los Angeles Movement Disorders in Chicago Movement Disorders in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease